Academic Journal
Προβολή σε EDS

The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review.
Συγγραφείς: Kirsch DE; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA., Grodin EN; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA., Leggio L; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland, USA., McKee SA; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA., Meredith LR; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA., Mereish EH; Department of Psychology, University of Maryland, College Park, Maryland, USA., Miranda R Jr; Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, USA., Nieto SJ; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA., O'Malley SS; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA., Schacht JP; Department of Psychiatry, University of Colorado School of Medicine, Aurora, Colorado, USA., Ray LA; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA.
Πηγή: Alcohol, clinical & experimental research [Alcohol Clin Exp Res (Hoboken)] 2025 Nov; Vol. 49 (11), pp. 2412-2426. Date of Electronic Publication: 2025 Sep 29.
Τύπος έκδοσης: Journal Article; Review
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley Periodicals Country of Publication: United States NLM ID: 9918609780906676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2993-7175 (Electronic) Linking ISSN: 29937175 NLM ISO Abbreviation: Alcohol Clin Exp Res (Hoboken) Subsets: MEDLINE
Imprint Name(s): Original Publication: Hoboken, NJ : Wiley Periodicals, [2023]-
Ιατρικοί όροι (MeSH): Alcoholism*/drug therapy , Alcoholism*/diagnosis , Alcoholism*/psychology , Drug Development*/methods , Cues*, Humans ; Craving
Περίληψη: The alcohol cue-exposure paradigm has a long and rich history in alcohol use disorder (AUD) research, contributing to the identification of risk factors, the recognition of craving as a core symptom, the understanding of AUD neurobiology, and the development of both pharmacological and behavioral treatments. The goal of this review was to evaluate the utility of the alcohol cue-exposure paradigm as a screening tool for AUD medication development and to provide recommendations for refinement of the paradigm. First, we review evidence supporting the predictive validity and clinical applicability of the alcohol cue-exposure paradigm. Second, we examine current practices in implementing the paradigm in AUD pharmacotherapy studies. Third, we highlight several areas for refinement and offer recommendations for the implementation of this paradigm. Finally, we outline key conclusions and actionable future directions. In summary, while the alcohol cue-exposure paradigm has an established foundation in the study of AUD pharmacotherapies, its future success hinges on a concerted effort to refine and standardize protocols and validate outcome measures in large-scale studies. Addressing these priorities could accelerate the development and regulatory approval of novel treatments for AUD.
(© 2025 The Author(s). Alcohol, Clinical and Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcohol.)
References: JCI Insight. 2024 Dec 20;9(24):. (PMID: 39704175)
Neuropsychopharmacology. 2009 Apr;34(5):1198-208. (PMID: 18563062)
J Neurosci. 2023 Mar 1;43(9):1600-1613. (PMID: 36657973)
Annu Rev Clin Psychol. 2010;6:591-606. (PMID: 20192791)
Psychopharmacology (Berl). 2008 Sep;200(1):141-50. (PMID: 18604601)
Alcohol Clin Exp Res. 2020 Jul;44(7):1431-1443. (PMID: 32363592)
Psychopharmacology (Berl). 2024 Aug;241(8):1679-1689. (PMID: 38613685)
Alcohol Res Health. 1999;23(3):174-8. (PMID: 10890812)
Transl Psychiatry. 2021 Jun 12;11(1):355. (PMID: 34120149)
Eur Arch Psychiatry Clin Neurosci. 2021 Aug;271(5):915-927. (PMID: 33884495)
Addiction. 2000 Aug;95 Suppl 2:S129-44. (PMID: 11002908)
J Stud Alcohol. 1994 Jul;55(4):487-94. (PMID: 7934057)
JAMA. 2023 Nov 7;330(17):1653-1665. (PMID: 37934220)
Psychopharmacology (Berl). 2001 Apr;155(1):27-34. (PMID: 11374333)
Addict Biol. 2013 Jan;18(1):121-33. (PMID: 22574861)
Prog Brain Res. 2016;224:401-18. (PMID: 26822368)
Am J Drug Alcohol Abuse. 2017 Mar;43(2):186-196. (PMID: 27439453)
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD001867. (PMID: 21154349)
JAMA Intern Med. 2014 Jan;174(1):70-7. (PMID: 24190578)
Neuropsychopharmacology. 2021 Jul;46(8):1414-1420. (PMID: 33558678)
Drugs. 2022 Feb;82(3):251-274. (PMID: 35133639)
Addict Biol. 2022 Jan;27(1):e13069. (PMID: 34132011)
Eur Neuropsychopharmacol. 2018 Nov;28(11):1206-1216. (PMID: 30217552)
JAMA. 2006 May 3;295(17):2003-17. (PMID: 16670409)
Alcohol Clin Exp Res. 2019 Jun;43(6):1263-1272. (PMID: 31099903)
Alcohol Clin Exp Res. 2014 Nov;38(11):2754-62. (PMID: 25421512)
Nat Protoc. 2022 Mar;17(3):567-595. (PMID: 35121856)
Alcohol Clin Exp Res (Hoboken). 2024 Sep;48(9):1772-1783. (PMID: 38960894)
Addict Biol. 2017 Nov;22(6):1515-1527. (PMID: 27411969)
Addict Biol. 2014 Sep;19(5):941-54. (PMID: 23489253)
Alcohol Clin Exp Res. 1999 Aug;23(8):1386-94. (PMID: 10470982)
Mol Psychiatry. 2020 Feb;25(2):461-475. (PMID: 29728704)
Drug Alcohol Depend. 2024 Mar 1;256:111123. (PMID: 38367535)
Addiction. 2000 Aug;95 Suppl 2:S189-210. (PMID: 11002914)
ACS Chem Neurosci. 2015 Apr 15;6(4):522-5. (PMID: 25734247)
J Clin Psychopharmacol. 2012 Oct;32(5):661-5. (PMID: 22926600)
Pharmacol Biochem Behav. 2013 Feb;103(4):784-91. (PMID: 23262301)
Psychopharmacology (Berl). 2014 Sep;231(18):3799-807. (PMID: 24647921)
Am J Drug Alcohol Abuse. 2020;46(1):131-138. (PMID: 31295037)
J Abnorm Psychol. 1987 May;96(2):122-6. (PMID: 3584660)
Clin Psychol Rev. 2022 Feb;91:102110. (PMID: 34864497)
Addict Behav. 1990;15(2):137-46. (PMID: 2343787)
Am J Psychiatry. 2023 Jun 1;180(6):445-453. (PMID: 36987598)
Alcohol Alcohol. 2025 Jan 19;60(2):. (PMID: 39829301)
Annu Rev Pharmacol Toxicol. 2016;56:299-322. (PMID: 26514207)
Addict Biol. 2020 Jan;25(1):e12717. (PMID: 30748046)
Neuropsychopharmacology. 2000 May;22(5):480-92. (PMID: 10731623)
Alcohol Clin Exp Res. 2018 Sep;42(9):1612-1622. (PMID: 29969156)
Neuroimage. 2011 May 1;56(1):61-8. (PMID: 21316465)
Addict Behav. 2024 Aug;155:108028. (PMID: 38640885)
Biol Psychiatry. 2011 Jun 1;69(11):1060-6. (PMID: 21292243)
Trials. 2014 Apr 23;15:139. (PMID: 24755011)
J Consult Clin Psychol. 1994 Jun;62(3):620-6. (PMID: 8063989)
Alcohol Clin Exp Res. 1999 Feb;23(2):195-203. (PMID: 10069545)
Alcohol Clin Exp Res (Hoboken). 2025 Nov;49(11):2412-2426. (PMID: 41017297)
Clin Psychol Rev. 2009 Aug;29(6):519-34. (PMID: 19577831)
Addict Biol. 2009 Jan;14(1):73-83. (PMID: 18855801)
Psychopharmacology (Berl). 2025 Jan;242(1):149-160. (PMID: 39102049)
Nat Rev Rheumatol. 2018 Jun;14(6):354-362. (PMID: 29760435)
J Stud Alcohol. 1994 Mar;55(2):224-9. (PMID: 8189743)
J Neurosci Res. 2021 Jan;99(1):309-323. (PMID: 32333417)
Am J Drug Alcohol Abuse. 2025 Jan 02;51(1):14-30. (PMID: 39868972)
Eur Neuropsychopharmacol. 2007 Jul;17(8):558-66. (PMID: 17379484)
Alcohol Clin Exp Res. 2012 Feb;36(2):351-60. (PMID: 21919922)
Transl Psychiatry. 2017 Apr 25;7(4):e1108. (PMID: 28440812)
Addiction. 2000 Aug;95 Suppl 2:S229-36. (PMID: 11002917)
Alcohol Clin Exp Res. 2012 Jun;36(6):972-83. (PMID: 22309888)
JAMA. 2014 May 14;311(18):1889-900. (PMID: 24825644)
J Abnorm Psychol. 1997 May;106(2):243-50. (PMID: 9131844)
Alcohol Clin Exp Res (Hoboken). 2023 Sep;47(9):1629-1645. (PMID: 37423771)
Neuropsychopharmacology. 2017 Dec;42(13):2640-2653. (PMID: 28409564)
World J Cardiol. 2014 May 26;6(5):245-52. (PMID: 24891935)
J Neural Transm (Vienna). 2000;107(6):721-30. (PMID: 10943912)
Neurosci Biobehav Rev. 2021 Sep;128:294-310. (PMID: 34171325)
JAMA Psychiatry. 2024 Apr 01;81(4):414-425. (PMID: 38324323)
Biol Sex Differ. 2022 Jun 27;13(1):34. (PMID: 35761351)
Neuropsychopharmacology. 2022 Oct;47(11):1953-1960. (PMID: 35523943)
Alcohol Clin Exp Res (Hoboken). 2024 Dec;48(12):2352-2363. (PMID: 39623527)
Arch Intern Med. 2007 Apr 9;167(7):716-21. (PMID: 17420431)
Psychopharmacology (Berl). 2009 Jul;205(1):53-62. (PMID: 19319508)
Arch Gen Psychiatry. 2008 Apr;65(4):466-75. (PMID: 18391135)
Neurobiol Stress. 2019 Feb 08;10:100149. (PMID: 30949562)
Neurobiol Stress. 2024 Aug 10;32:100668. (PMID: 39252986)
Psychopharmacology (Berl). 2021 May;238(5):1291-1302. (PMID: 30788529)
J Clin Invest. 2015 Aug 3;125(8):3193-7. (PMID: 26121746)
Grant Information: K24 AA025704 United States AA NIAAA NIH HHS; K01 AA029712 United States AA NIAAA NIH HHS; K24 AA026326 United States AA NIAAA NIH HHS; K24AA025704 United States AA NIAAA NIH HHS; K24AA026326 United States AA NIAAA NIH HHS
Contributed Indexing: Keywords: addiction; alcohol use disorder; craving; cue reactivity; medications
Entry Date(s): Date Created: 20250929 Date Completed: 20251121 Latest Revision: 20260307
Update Code: 20260307
PubMed Central ID: PMC12638288
DOI: 10.1111/acer.70170
PMID: 41017297
Βάση Δεδομένων: MEDLINE
FullText Text:
  Availability: 0
Header DbId: cmedm
DbLabel: MEDLINE
An: 41017297
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kirsch+DE%22">Kirsch DE</searchLink>; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Grodin+EN%22">Grodin EN</searchLink>; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Leggio+L%22">Leggio L</searchLink>; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22McKee+SA%22">McKee SA</searchLink>; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Meredith+LR%22">Meredith LR</searchLink>; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Mereish+EH%22">Mereish EH</searchLink>; Department of Psychology, University of Maryland, College Park, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Miranda+R+Jr%22">Miranda R Jr</searchLink>; Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, USA.<br /><searchLink fieldCode="AU" term="%22Nieto+SJ%22">Nieto SJ</searchLink>; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22O'Malley+SS%22">O'Malley SS</searchLink>; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Schacht+JP%22">Schacht JP</searchLink>; Department of Psychiatry, University of Colorado School of Medicine, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Ray+LA%22">Ray LA</searchLink>; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918609780906676%22">Alcohol, clinical & experimental research</searchLink> [Alcohol Clin Exp Res (Hoboken)] 2025 Nov; Vol. 49 (11), pp. 2412-2426. <i>Date of Electronic Publication: </i>2025 Sep 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley+Periodicals%22">Wiley Periodicals </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918609780906676 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2993-7175 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2229937175%22">29937175 </searchLink><i>NLM ISO Abbreviation: </i>Alcohol Clin Exp Res (Hoboken) <i>Subsets: </i>MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: <i>Original Publication</i>: Hoboken, NJ : Wiley Periodicals, [2023]-
– Name: SubjectMESH
  Label: MeSH Terms
  Group: Su
  Data: <searchLink fieldCode="MM" term="%22Alcoholism%22">Alcoholism*</searchLink>/<searchLink fieldCode="MM" term="%22Alcoholism+drug+therapy%22">drug therapy</searchLink> <br /><searchLink fieldCode="MM" term="%22Alcoholism%22">Alcoholism*</searchLink>/<searchLink fieldCode="MM" term="%22Alcoholism+diagnosis%22">diagnosis</searchLink> <br /><searchLink fieldCode="MM" term="%22Alcoholism%22">Alcoholism*</searchLink>/<searchLink fieldCode="MM" term="%22Alcoholism+psychology%22">psychology</searchLink> <br /><searchLink fieldCode="MM" term="%22Drug+Development%22">Drug Development*</searchLink>/<searchLink fieldCode="MM" term="%22Drug+Development+methods%22">methods</searchLink> <br /><searchLink fieldCode="MM" term="%22Cues%22">Cues*</searchLink><br /><searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Craving%22">Craving</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The alcohol cue-exposure paradigm has a long and rich history in alcohol use disorder (AUD) research, contributing to the identification of risk factors, the recognition of craving as a core symptom, the understanding of AUD neurobiology, and the development of both pharmacological and behavioral treatments. The goal of this review was to evaluate the utility of the alcohol cue-exposure paradigm as a screening tool for AUD medication development and to provide recommendations for refinement of the paradigm. First, we review evidence supporting the predictive validity and clinical applicability of the alcohol cue-exposure paradigm. Second, we examine current practices in implementing the paradigm in AUD pharmacotherapy studies. Third, we highlight several areas for refinement and offer recommendations for the implementation of this paradigm. Finally, we outline key conclusions and actionable future directions. In summary, while the alcohol cue-exposure paradigm has an established foundation in the study of AUD pharmacotherapies, its future success hinges on a concerted effort to refine and standardize protocols and validate outcome measures in large-scale studies. Addressing these priorities could accelerate the development and regulatory approval of novel treatments for AUD.<br /> (© 2025 The Author(s). Alcohol, Clinical and Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcohol.)
– Name: Ref
  Label: References
  Group: RefInfo
  Data: JCI Insight. 2024 Dec 20;9(24):. (PMID: <searchLink fieldCode="PM" term="%2239704175%22">39704175)</searchLink><br />Neuropsychopharmacology. 2009 Apr;34(5):1198-208. (PMID: <searchLink fieldCode="PM" term="%2218563062%22">18563062)</searchLink><br />J Neurosci. 2023 Mar 1;43(9):1600-1613. (PMID: <searchLink fieldCode="PM" term="%2236657973%22">36657973)</searchLink><br />Annu Rev Clin Psychol. 2010;6:591-606. (PMID: <searchLink fieldCode="PM" term="%2220192791%22">20192791)</searchLink><br />Psychopharmacology (Berl). 2008 Sep;200(1):141-50. (PMID: <searchLink fieldCode="PM" term="%2218604601%22">18604601)</searchLink><br />Alcohol Clin Exp Res. 2020 Jul;44(7):1431-1443. (PMID: <searchLink fieldCode="PM" term="%2232363592%22">32363592)</searchLink><br />Psychopharmacology (Berl). 2024 Aug;241(8):1679-1689. (PMID: <searchLink fieldCode="PM" term="%2238613685%22">38613685)</searchLink><br />Alcohol Res Health. 1999;23(3):174-8. (PMID: <searchLink fieldCode="PM" term="%2210890812%22">10890812)</searchLink><br />Transl Psychiatry. 2021 Jun 12;11(1):355. (PMID: <searchLink fieldCode="PM" term="%2234120149%22">34120149)</searchLink><br />Eur Arch Psychiatry Clin Neurosci. 2021 Aug;271(5):915-927. (PMID: <searchLink fieldCode="PM" term="%2233884495%22">33884495)</searchLink><br />Addiction. 2000 Aug;95 Suppl 2:S129-44. (PMID: <searchLink fieldCode="PM" term="%2211002908%22">11002908)</searchLink><br />J Stud Alcohol. 1994 Jul;55(4):487-94. (PMID: <searchLink fieldCode="PM" term="%227934057%22">7934057)</searchLink><br />JAMA. 2023 Nov 7;330(17):1653-1665. (PMID: <searchLink fieldCode="PM" term="%2237934220%22">37934220)</searchLink><br />Psychopharmacology (Berl). 2001 Apr;155(1):27-34. (PMID: <searchLink fieldCode="PM" term="%2211374333%22">11374333)</searchLink><br />Addict Biol. 2013 Jan;18(1):121-33. (PMID: <searchLink fieldCode="PM" term="%2222574861%22">22574861)</searchLink><br />Prog Brain Res. 2016;224:401-18. (PMID: <searchLink fieldCode="PM" term="%2226822368%22">26822368)</searchLink><br />Am J Drug Alcohol Abuse. 2017 Mar;43(2):186-196. (PMID: <searchLink fieldCode="PM" term="%2227439453%22">27439453)</searchLink><br />Cochrane Database Syst Rev. 2010 Dec 08;(12):CD001867. (PMID: <searchLink fieldCode="PM" term="%2221154349%22">21154349)</searchLink><br />JAMA Intern Med. 2014 Jan;174(1):70-7. (PMID: <searchLink fieldCode="PM" term="%2224190578%22">24190578)</searchLink><br />Neuropsychopharmacology. 2021 Jul;46(8):1414-1420. (PMID: <searchLink fieldCode="PM" term="%2233558678%22">33558678)</searchLink><br />Drugs. 2022 Feb;82(3):251-274. (PMID: <searchLink fieldCode="PM" term="%2235133639%22">35133639)</searchLink><br />Addict Biol. 2022 Jan;27(1):e13069. (PMID: <searchLink fieldCode="PM" term="%2234132011%22">34132011)</searchLink><br />Eur Neuropsychopharmacol. 2018 Nov;28(11):1206-1216. (PMID: <searchLink fieldCode="PM" term="%2230217552%22">30217552)</searchLink><br />JAMA. 2006 May 3;295(17):2003-17. (PMID: <searchLink fieldCode="PM" term="%2216670409%22">16670409)</searchLink><br />Alcohol Clin Exp Res. 2019 Jun;43(6):1263-1272. (PMID: <searchLink fieldCode="PM" term="%2231099903%22">31099903)</searchLink><br />Alcohol Clin Exp Res. 2014 Nov;38(11):2754-62. (PMID: <searchLink fieldCode="PM" term="%2225421512%22">25421512)</searchLink><br />Nat Protoc. 2022 Mar;17(3):567-595. (PMID: <searchLink fieldCode="PM" term="%2235121856%22">35121856)</searchLink><br />Alcohol Clin Exp Res (Hoboken). 2024 Sep;48(9):1772-1783. (PMID: <searchLink fieldCode="PM" term="%2238960894%22">38960894)</searchLink><br />Addict Biol. 2017 Nov;22(6):1515-1527. (PMID: <searchLink fieldCode="PM" term="%2227411969%22">27411969)</searchLink><br />Addict Biol. 2014 Sep;19(5):941-54. (PMID: <searchLink fieldCode="PM" term="%2223489253%22">23489253)</searchLink><br />Alcohol Clin Exp Res. 1999 Aug;23(8):1386-94. (PMID: <searchLink fieldCode="PM" term="%2210470982%22">10470982)</searchLink><br />Mol Psychiatry. 2020 Feb;25(2):461-475. (PMID: <searchLink fieldCode="PM" term="%2229728704%22">29728704)</searchLink><br />Drug Alcohol Depend. 2024 Mar 1;256:111123. (PMID: <searchLink fieldCode="PM" term="%2238367535%22">38367535)</searchLink><br />Addiction. 2000 Aug;95 Suppl 2:S189-210. (PMID: <searchLink fieldCode="PM" term="%2211002914%22">11002914)</searchLink><br />ACS Chem Neurosci. 2015 Apr 15;6(4):522-5. (PMID: <searchLink fieldCode="PM" term="%2225734247%22">25734247)</searchLink><br />J Clin Psychopharmacol. 2012 Oct;32(5):661-5. (PMID: <searchLink fieldCode="PM" term="%2222926600%22">22926600)</searchLink><br />Pharmacol Biochem Behav. 2013 Feb;103(4):784-91. (PMID: <searchLink fieldCode="PM" term="%2223262301%22">23262301)</searchLink><br />Psychopharmacology (Berl). 2014 Sep;231(18):3799-807. (PMID: <searchLink fieldCode="PM" term="%2224647921%22">24647921)</searchLink><br />Am J Drug Alcohol Abuse. 2020;46(1):131-138. (PMID: <searchLink fieldCode="PM" term="%2231295037%22">31295037)</searchLink><br />J Abnorm Psychol. 1987 May;96(2):122-6. (PMID: <searchLink fieldCode="PM" term="%223584660%22">3584660)</searchLink><br />Clin Psychol Rev. 2022 Feb;91:102110. (PMID: <searchLink fieldCode="PM" term="%2234864497%22">34864497)</searchLink><br />Addict Behav. 1990;15(2):137-46. (PMID: <searchLink fieldCode="PM" term="%222343787%22">2343787)</searchLink><br />Am J Psychiatry. 2023 Jun 1;180(6):445-453. (PMID: <searchLink fieldCode="PM" term="%2236987598%22">36987598)</searchLink><br />Alcohol Alcohol. 2025 Jan 19;60(2):. (PMID: <searchLink fieldCode="PM" term="%2239829301%22">39829301)</searchLink><br />Annu Rev Pharmacol Toxicol. 2016;56:299-322. (PMID: <searchLink fieldCode="PM" term="%2226514207%22">26514207)</searchLink><br />Addict Biol. 2020 Jan;25(1):e12717. (PMID: <searchLink fieldCode="PM" term="%2230748046%22">30748046)</searchLink><br />Neuropsychopharmacology. 2000 May;22(5):480-92. (PMID: <searchLink fieldCode="PM" term="%2210731623%22">10731623)</searchLink><br />Alcohol Clin Exp Res. 2018 Sep;42(9):1612-1622. (PMID: <searchLink fieldCode="PM" term="%2229969156%22">29969156)</searchLink><br />Neuroimage. 2011 May 1;56(1):61-8. (PMID: <searchLink fieldCode="PM" term="%2221316465%22">21316465)</searchLink><br />Addict Behav. 2024 Aug;155:108028. (PMID: <searchLink fieldCode="PM" term="%2238640885%22">38640885)</searchLink><br />Biol Psychiatry. 2011 Jun 1;69(11):1060-6. (PMID: <searchLink fieldCode="PM" term="%2221292243%22">21292243)</searchLink><br />Trials. 2014 Apr 23;15:139. (PMID: <searchLink fieldCode="PM" term="%2224755011%22">24755011)</searchLink><br />J Consult Clin Psychol. 1994 Jun;62(3):620-6. (PMID: <searchLink fieldCode="PM" term="%228063989%22">8063989)</searchLink><br />Alcohol Clin Exp Res. 1999 Feb;23(2):195-203. (PMID: <searchLink fieldCode="PM" term="%2210069545%22">10069545)</searchLink><br />Alcohol Clin Exp Res (Hoboken). 2025 Nov;49(11):2412-2426. (PMID: <searchLink fieldCode="PM" term="%2241017297%22">41017297)</searchLink><br />Clin Psychol Rev. 2009 Aug;29(6):519-34. (PMID: <searchLink fieldCode="PM" term="%2219577831%22">19577831)</searchLink><br />Addict Biol. 2009 Jan;14(1):73-83. (PMID: <searchLink fieldCode="PM" term="%2218855801%22">18855801)</searchLink><br />Psychopharmacology (Berl). 2025 Jan;242(1):149-160. (PMID: <searchLink fieldCode="PM" term="%2239102049%22">39102049)</searchLink><br />Nat Rev Rheumatol. 2018 Jun;14(6):354-362. (PMID: <searchLink fieldCode="PM" term="%2229760435%22">29760435)</searchLink><br />J Stud Alcohol. 1994 Mar;55(2):224-9. (PMID: <searchLink fieldCode="PM" term="%228189743%22">8189743)</searchLink><br />J Neurosci Res. 2021 Jan;99(1):309-323. (PMID: <searchLink fieldCode="PM" term="%2232333417%22">32333417)</searchLink><br />Am J Drug Alcohol Abuse. 2025 Jan 02;51(1):14-30. (PMID: <searchLink fieldCode="PM" term="%2239868972%22">39868972)</searchLink><br />Eur Neuropsychopharmacol. 2007 Jul;17(8):558-66. (PMID: <searchLink fieldCode="PM" term="%2217379484%22">17379484)</searchLink><br />Alcohol Clin Exp Res. 2012 Feb;36(2):351-60. (PMID: <searchLink fieldCode="PM" term="%2221919922%22">21919922)</searchLink><br />Transl Psychiatry. 2017 Apr 25;7(4):e1108. (PMID: <searchLink fieldCode="PM" term="%2228440812%22">28440812)</searchLink><br />Addiction. 2000 Aug;95 Suppl 2:S229-36. (PMID: <searchLink fieldCode="PM" term="%2211002917%22">11002917)</searchLink><br />Alcohol Clin Exp Res. 2012 Jun;36(6):972-83. (PMID: <searchLink fieldCode="PM" term="%2222309888%22">22309888)</searchLink><br />JAMA. 2014 May 14;311(18):1889-900. (PMID: <searchLink fieldCode="PM" term="%2224825644%22">24825644)</searchLink><br />J Abnorm Psychol. 1997 May;106(2):243-50. (PMID: <searchLink fieldCode="PM" term="%229131844%22">9131844)</searchLink><br />Alcohol Clin Exp Res (Hoboken). 2023 Sep;47(9):1629-1645. (PMID: <searchLink fieldCode="PM" term="%2237423771%22">37423771)</searchLink><br />Neuropsychopharmacology. 2017 Dec;42(13):2640-2653. (PMID: <searchLink fieldCode="PM" term="%2228409564%22">28409564)</searchLink><br />World J Cardiol. 2014 May 26;6(5):245-52. (PMID: <searchLink fieldCode="PM" term="%2224891935%22">24891935)</searchLink><br />J Neural Transm (Vienna). 2000;107(6):721-30. (PMID: <searchLink fieldCode="PM" term="%2210943912%22">10943912)</searchLink><br />Neurosci Biobehav Rev. 2021 Sep;128:294-310. (PMID: <searchLink fieldCode="PM" term="%2234171325%22">34171325)</searchLink><br />JAMA Psychiatry. 2024 Apr 01;81(4):414-425. (PMID: <searchLink fieldCode="PM" term="%2238324323%22">38324323)</searchLink><br />Biol Sex Differ. 2022 Jun 27;13(1):34. (PMID: <searchLink fieldCode="PM" term="%2235761351%22">35761351)</searchLink><br />Neuropsychopharmacology. 2022 Oct;47(11):1953-1960. (PMID: <searchLink fieldCode="PM" term="%2235523943%22">35523943)</searchLink><br />Alcohol Clin Exp Res (Hoboken). 2024 Dec;48(12):2352-2363. (PMID: <searchLink fieldCode="PM" term="%2239623527%22">39623527)</searchLink><br />Arch Intern Med. 2007 Apr 9;167(7):716-21. (PMID: <searchLink fieldCode="PM" term="%2217420431%22">17420431)</searchLink><br />Psychopharmacology (Berl). 2009 Jul;205(1):53-62. (PMID: <searchLink fieldCode="PM" term="%2219319508%22">19319508)</searchLink><br />Arch Gen Psychiatry. 2008 Apr;65(4):466-75. (PMID: <searchLink fieldCode="PM" term="%2218391135%22">18391135)</searchLink><br />Neurobiol Stress. 2019 Feb 08;10:100149. (PMID: <searchLink fieldCode="PM" term="%2230949562%22">30949562)</searchLink><br />Neurobiol Stress. 2024 Aug 10;32:100668. (PMID: <searchLink fieldCode="PM" term="%2239252986%22">39252986)</searchLink><br />Psychopharmacology (Berl). 2021 May;238(5):1291-1302. (PMID: <searchLink fieldCode="PM" term="%2230788529%22">30788529)</searchLink><br />J Clin Invest. 2015 Aug 3;125(8):3193-7. (PMID: <searchLink fieldCode="PM" term="%2226121746%22">26121746)</searchLink>
– Name: GrantInfo
  Label: Grant Information
  Group: Grant
  Data: K24 AA025704 United States AA NIAAA NIH HHS; K01 AA029712 United States AA NIAAA NIH HHS; K24 AA026326 United States AA NIAAA NIH HHS; K24AA025704 United States AA NIAAA NIH HHS; K24AA026326 United States AA NIAAA NIH HHS
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: <i>Keywords: </i>addiction; alcohol use disorder; craving; cue reactivity; medications
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: <i>Date Created: </i>20250929 <i>Date Completed: </i>20251121 <i>Latest Revision: </i>20260307
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260307
– Name: PubmedCentralID
  Label: PubMed Central ID
  Group: ID
  Data: PMC12638288
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1111/acer.70170
– Name: AN
  Label: PMID
  Group: ID
  Data: 41017297
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=41017297
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/acer.70170
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2412
    Subjects:
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Craving
        Type: general
      – SubjectFull: Alcoholism drug therapy
        Type: general
      – SubjectFull: Alcoholism diagnosis
        Type: general
      – SubjectFull: Alcoholism psychology
        Type: general
      – SubjectFull: Drug Development methods
        Type: general
      – SubjectFull: Cues
        Type: general
    Titles:
      – TitleFull: The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kirsch DE
      – PersonEntity:
          Name:
            NameFull: Grodin EN
      – PersonEntity:
          Name:
            NameFull: Leggio L
      – PersonEntity:
          Name:
            NameFull: McKee SA
      – PersonEntity:
          Name:
            NameFull: Meredith LR
      – PersonEntity:
          Name:
            NameFull: Mereish EH
      – PersonEntity:
          Name:
            NameFull: Miranda R Jr
      – PersonEntity:
          Name:
            NameFull: Nieto SJ
      – PersonEntity:
          Name:
            NameFull: O'Malley SS
      – PersonEntity:
          Name:
            NameFull: Schacht JP
      – PersonEntity:
          Name:
            NameFull: Ray LA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2993-7175
          Numbering:
            – Type: volume
              Value: 49
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Alcohol, clinical & experimental research
              Type: main
ResultId 1